Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Videos

  •   Email
  •   Print
  •   Share
  • Avastin not as beneficial to older lung cancer patients
  • 1:28
  • Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, comments on a study that found adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare. Based on these results, the authors recommend that bevacizumab should not automatically be administered together with carboplatin-paclitaxel for older patients with non-small cell lung cancer. Rather, clinicians should exercise caution in making treatment recommendations and use bevacizumab judiciously for their patients.

Tags: chemotherapy, LungCancer